Harvard and MIT’s Broad Institute, through the The Slim Initiative for Genomic Medicine in the Americas (SIGMA), along with others, will use the funds to focus on advancing genomic medicine and diagnostics – especially diagnostic tools for breast cancer and diabetes. Read the details here.